Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
EMERYVILLE, Calif., Nov. 08, 2016 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, will participate in a fireside chat at the Stifel 2016 Healthcare Conference.
Stifel 2016 Healthcare Conference
| Date: | Tuesday, November 15, 2016 | |
| Time: | 3:45 pm Eastern Time / 12:45 pm Pacific Time | |
| Location: | New York, NY |
The presentation will be webcast live and can be accessed on Zogenix's Investor Relations website at ir.zogenix.com.
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT: Investors: Andrew McDonald Founding Partner, LifeSci Advisors LLC 646-597-6987 | [email protected]
